Вики-госпиталь
Госпитализация в Москве
Вики-госпиталь - главная ›› На русском ›› "Похудательная" вакцина уже проходит испытания на людях


2 

Статья из Комсомольской правды, похоже больше на преувеличение. Интересующиеся могут почитать работу на английском на этой же странице.

Елена ИОНОВА,  — 03.01.2011

 

 

Хорошая новость для тех, кто уже отчаялся стать стройняшкой, терзая себя диетами и печальными мыслями, как же влезть в новое платье с зауженной талией. Скандинавские ученые разработали вакцину, которая помогает сбрасывать лишние кило и не набирать их снова. В ходе эксперимента добровольцы обоих полов смогли сбросить почти по 10 кг за полгода.

Вакцина содержит вещество глюкагонподобный пептид-1 (его уже несколько лет успешно используют для лечения диабета и его осложнений).

«Антижировая» прививка уже испробована на 550 добровольцах обоих полов, имеющих избыточный вес. Некоторым из них препарат давался ежедневно, некоторым вместо него - давали пустышки или орлистат (вещество, которое блокирует всасывание лишних жиров). Результаты были таковы: люди, прошедшие вакцинацию от ожирения, через полгода сбросили в среднем по 10 кг лишнего веса. Это в два раза больше, чем те, кто принимал орлистат или плацебо.

Пока что это чисто научная разработка, но специалисты уверяют, что испытания будут завершены через год, и тогда прививка от ожирения появится в арсенале диетологов и эндокринологов.

 

Glucagon-like peptide.

Glucagon-like peptide 1 (GLP-1) is a gut peptide that has been under investigation for use as both a diabetes and obesity medication. Unlike current medications that affect catecholamine and serotonin pathways, GLP-1 inhibits gastric emptying. Delayed gastric emptying limits food intake, stimulates insulin, and inhibits glucagon secretion after a meal. In diabetics this action reduces postprandial hypoglycemia, and may result in weight loss.

THE ILEAL BRAKE MECHANISM
E. the ileal brake mechanism inhibits gastric emptying, inhibits food intake, stimulates insulin and inhibits glucagon secretion afer a meal

GLP-1 may affect the "ileal brake mechanism", an important regulator of gastrointestinal function. Unabsorbed nutrients in the ileum, especially fat, inhibit gastric emptying, decrease intestinal motility, transit and pancreatic secretions. Researchers speculate that vagal activity may contribute to the inhibitory effect of GLP-1 on gastric emptying. Many studies have shown that obese patients have accelerated gastric emptying and weaker GLP-1 and cholecystokinin (CCK) response as compared to lean controls. Both weight loss and gastric surgery have been shown to decrease the rate.

In a recent study, a group of 20 men ate less and felt fuller when infused with GLP-1 than when given placebo.
Subjects. 20 normal weight non-smoking men ages 20-31 years old with a body mass index (BMI) of 20.3 to 25.7 and body fat percentage of 9.7 to 19.5 percent. The men had no family history of obesity or diabetes and were not "elite athletes". One subject was excluded from the data analysis because of a severe headache on the second day.

Method. The subjects were tested on two occasions in a placebo-controlled, randomized, blinded, crossover study. The two test days were separated by at least three weeks, but not more than seven. Subjects restrained from strenuous physical activity and ate a weight-maintaining, standardized diet for 2 days before the study. On the date of the experiment the men were told to take the least strenuous means of transportation to the site. They rested for 45 minutes after arriving at the facility, and then a fasting blood sample was taken. Two different test meals were used, a fixed-size breakfast and an "ad libitum" lunch.

Results. The men receiving the GLP-1 infusion reported enhanced satiety after breakfast and ate 12 percent less at lunch.

GLP-1 and obesity. There have been few studies on the effect of GLP-1 in obese people. But those studies show that it is likely to promote weight loss. A 1997 study showed comparable glucose lowering effects in both lean and obese subjects with type-2 diabetes, indicating that GLP-1 receptors function normally in the obese. 1 These findings suggest that GLP-1 will normalize the accelerated gastric emptying in obese people, and reverse morbid obesity.

Two hurdles need to be overcome before GLP-1 can be produced for use in patients 1) an oral formulation of GLP-1 needs to be developed, and 2) testing on long term appetite suppression needs to be conducted. As a peptide, GLP-1 cannot be taken orally since it is metabolized rapidly. The intact peptide only stays in circulation for 1.5 minutes. The experiment above used continuous infusion.

Because of the method of testing, long term human trials on GLP-1 and appetite have not been conducted

2 


Вакцина против ожирения
Чудодейственную вакцину разработали скандинавские ученые.